Healthcare Industry News: neuromodulation
News Release - November 13, 2018
NeuroStar(R) Advanced Therapy and Transformations TMS Expanding Partnership to Increase Patient Access to Depression TreatmentTMS therapy provider will be offering NeuroStar Advanced Therapy at six new locations
MALVERN, Pa., Nov. 13, 2018 -- (Healthcare Sales & Marketing Network) -- NeuroStar® Advanced Therapy, the established leader in transcranial magnetic stimulation (TMS), announced an expanded partnership with GRW Health, the parent company of Harmony and Transformations TMS. Transformations TMS will offer NeuroStar Advanced Therapy at six new locations across Pennsylvania and West Virginia. Harmony, a clinic dedicated to the treatment of mental illness and restoration of mental well-being, has offered NeuroStar at three of its locations since December 2017. With this most recent expansion, GRW Health will now have 11 NeuroStar TMS systems installed across their nine locations.
NeuroStar Advanced Therapy uses magnetic pulses to awaken areas of the brain that are underactive in depression. With its advanced technology, NeuroStar Advanced Therapy offers doctors real-time feedback and delivers enhanced care with its precise and accurate targeting, providing reliable and consistent treatment. In an open-label clinical trial, 58% of patients significantly responded to treatment, and 37% achieved complete remission of their depression symptoms with NeuroStar Advanced Therapy TMS.1
"I am thrilled to be expanding our relationship with GRW Health to increase patient access to this transformative treatment and help more people find relief from their depression," said Chris Thatcher, President and CEO of Neuronetics, Inc. "GRW Health's increased investment in NeuroStar TMS demonstrates their commitment to the proven efficacy of this non-drug treatment option and its ability to transform lives."
In 2018, Transformations TMS has already treated more than 75 patients and expects to see more than 100 patients across the Transformations TMS locations by the end of the year.
"We strive for the highest quality of psychiatric care and we're excited to offer NeuroStar Advanced Therapy at more of our locations across Pennsylvania and West Virginia," said Dr. Ryan Wakim, founder and president of GRW Health. "We have a committed team looking to help alleviate our patients' depression symptoms as much as possible, and we know NeuroStar works and provides our patients with a chance at long-term remission from depression. In fact, I've been so impressed by the results I've seen, I've even recommended NeuroStar to my own family members struggling with depression."
Since receiving FDA clearance in 2008 as a safe and effective treatment for adult patients with MDD, NeuroStar Advanced Therapy has become a game-changer in the treatment of depression and offers hope to the 5.5 million adults in the U.S. treated for depression who do not achieve remission with antidepressant medication.234 With widespread insurance coverage by most commercial and government health plans including Medicare and Tricare, the non-drug therapy is available by prescription and typically administered daily in a doctor's office for four to six weeks, with treatment sessions performed in as little ~19 minutes.* Unlike electroconvulsive therapy (ECT), NeuroStar Advanced Therapy is non-invasive and allows patients to resume daily activities immediately following treatment sessions. It is also free from systemic side effects often associated with antidepressant medications.5
Transformations TMS locations will now include Denver, CO; Fox Chapel, PA; McMurray, PA; Monroeville, PA; Mt. Lebanon, PA; Robinson, PA; Wexford, PA; Weirton, WV and Wheeling, WV.
Visit www.NeuroStar.com for more information about NeuroStar Advanced Therapy.
About NeuroStar® Advanced Therapy
NeuroStar® Advanced Therapy is the established leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation. NeuroStar Advanced Therapy is the #1 TMS choice of doctors for patients with MDD, and is widely available across the United States.
NeuroStar is widely reimbursed by most commercial and government health plans, including Medicare and Tricare. In addition, there are programs in place, such as NeuroStar Reimbursement Support, to help patients and providers obtain coverage and reimbursement for NeuroStar Advanced Therapy.
NeuroStar is indicated for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were four times more likely to achieve remission compared to patients receiving sham treatment (P = 0.0173; odds ratio = 4.05).6 The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in people with non-removable conductive metal in or near the head.
NeuroStar® is a registered trademark of Neuronetics, Inc. (NASDAQ: STIM). For more information and full safety and prescribing information, visit www.neurostar.com.
1 Carpenter LL, et al. Depress Anxiety, (2012)
* Treatment time may vary depending on doctor's recommendation.
2 Kessler RC, et al. JAMA, (2003)
3 https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml, accessed 1/16/2018
4 Gaynes BN et al., Cleveland Clinic Journal of Medicine 2008;75(1):57-66
5 Janicak PG, et al. J Clin Psychiatry, (2008)
6 George MS, et al. Arch Gen Psychiatry, (2010)
Source: NeuroStar Advanced Therapy
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.